ClinicalTrials.gg
CompletedNCT07238816Updated Jun 17, 2026

A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People

A Phase 1 interventional study of NNC0442-0344 A in Haemophilia A, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
15th of 59
80 · median 38
Started
2025
with 3 others
Phase 1
27 of 92
1 open now
Registered
90th of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 15th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2025, is one of 27 in phase 1, and was the 90th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms. Participants will take the study medicine after an overnight fast. How long participants will need to fast depends on which group participants are in. After taking the study medicine, participants will need to fast again. The study will last for up to 9.5 weeks.

03

Conditions studied

  • Haemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male.
  • Age 18-45 years (both inclusive) at the time of signing .
  • between 18.5 and 29.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening.
  • Body weight between 60.0 and 100.0 kilogram (kg) (both inclusive) at screening.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Factor VIII activity greater than or equal to (≥) 150 percentage (%) at screening.
  • Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
  • Any of the thrombophilia markers listed below:
  • Lupus anticoagulant, anti-cardiolipin antibody Immunoglobulin G (IgG) and Immunoglobulin M (IgM) or anti-β2 glycoprotein I antibody (IgG and IgM) outside the normal laboratory range at screening.
  • Heterozygosity or homozygosity for the factor V Leiden mutation (G1691A) OR heterozygosity or homozygosity for the prothrombin mutation (G20210A) OR compound heterozygosity for the factor V Leiden (G1691A) and prothrombin mutation (G20210A).
  • Protein C, protein S or antithrombin below the lower normal laboratory range.
  • Any known coagulation disorders.
  • Presence of gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Group A

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

  • Experimental
    Group B

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

  • Experimental
    Group C

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

  • Active comparator
    Reference dose

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

Interventions

  • NNC0442-0344 A will be administered orally.

    Also known as: Inno8

06

What researchers measure

Primary outcomes

  1. AUC0-∞: the area under the plasma Inno8 concentration-time curve from time 0 to infinity after a single oral dose

    Measured as nanograms\*day per millilitre (ng\*day/mL).

    Time frame: From baseline (Day 1) to day 17

Secondary outcomes

  1. Cmax: Maximum observed plasma Inno8 concentration after a single oral dose

    Measured as nanograms per millilitre (ng/mL).

    Time frame: From baseline (Day 1) to day 17

  2. Tmax: The time to maximum observed plasma Inno8 concentration after a single oral dose

    Measured as hours.

    Time frame: From baseline (Day 1) to day 17

  3. Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From time of dosing (Day 1) to day 36

  4. Change in D-dimer

    Measured as absolute (ng/mL) and percentage (%).

    Time frame: From baseline (Day 1) to day 36

  5. Change in prothrombin fragment 1 and 2

    Measured as absolute \[(picomoles per litre) pmol/L\] and %.

    Time frame: From baseline (Day 1) to day 36

  6. Change in fibrinogen

    Measured as absolute \[(milligrams per decilitre) mg/dL\] and %.

    Time frame: From baseline (Day 1) to day 36

  7. Change in platelets

    Measured as absolute \[(ten to the ninth power per litre) 10\^9/L\] and %.

    Time frame: From baseline (Day 1) to day 36

  8. Change in FIX antigen

    Measured as %.

    Time frame: From baseline (Day 1) to day 36

  9. Change in FX antigen

    Measured as %.

    Time frame: From baseline (Day 1) to day 36

07

Study locations

1 site
  • Altasciences Clinical LA, Inc.
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in May 2026, 5 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartActual
Nov 18, 2025
Primary completionActual
May 8, 2026
CompletionActual
May 8, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07238816
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Nov 18, 2025
Primary completion
May 8, 2026
Completion
May 8, 2026
Last update
Jun 17, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0442-0344

Start the discussion